Lowenstein Sandler LLP represented DelMar Pharmaceuticals in the transaction.
DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) and Adgero Biopharmaceuticals Holdings, Inc. have entered into a definitive merger agreement pursuant to which DelMar, a biopharmaceutical company focused on the development of new solid tumor cancer therapies, will acquire Adgero, a privately held biopharmaceutical company focused on the development of its late-stage photodynamic therapy platform for the treatment of serious cutaneous oncology indications. In an all-equity transaction, Adgero stockholders will receive shares of DelMar common stock for shares of Adgero common stock.
Subject to stockholder approval of both companies and other closing conditions, the transaction is expected to close in the third quarter of 2020, at which time DelMar is expected to change its name to Kintara Therapeutics, Inc. and trade on Nasdaq under the new ticker symbol “KTRA.”
This combination brings together DelMar’s first-in-class, DNA-targeting chemotherapeutic with proven anti-cancer activities with Adgero’s photodynamic therapy platform. The combined company expects to benefit from complementary capabilities along with greater financial resources and flexibility to engage in a wide range of research and development activities that the companies believe will ultimately result in the creation of sustainable, long-term growth.
The Lowenstein deal team representing DelMar included Michael J. Lerner (Picture), Steven M. Skolnick, Alan Wovsaniker, Kate Basmagian, Robert Bee, Justin Gindi, and Erica Perlmutter.
Involved fees earner: Kate Basmagian – Lowenstein Sandler LLP; Robert Bee – Lowenstein Sandler LLP; Justin Gindi – Lowenstein Sandler LLP; Michael Lerner – Lowenstein Sandler LLP; Erica Perlmutter – Lowenstein Sandler LLP; Steven Skolnick – Lowenstein Sandler LLP; Alan Wovsaniker – Lowenstein Sandler LLP;
Law Firms: Lowenstein Sandler LLP;
Clients: DelMar Pharmaceuticals;